Recruiting
Phase 2

LY900023

Sponsor:

Eli Lilly and Company

Code:

NCT05999994

Conditions

Neoplasms

Child

Adolescent

Eligibility Criteria

Sex: All

Age: 1 - 39

Healthy Volunteers: Not accepted

Interventions

Ramucirumab

Cyclophosphamide

Vinorelbine

Gemcitabine

Docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information